definiens: shall mean the period from the Effective Date until one hundred eighty ( 180 ) days after the Completion of the Existing Renal Trial ( the ) ; provided, however, that if JT reasonably concludes ( after good faith discussions with CG ) during the Initial MRCC Decision Period that the Renal Data then existing is insufficient to proceed with further clinical development of metastatic renal cell carcinomas, then JT may so advise CG prior to the end of such Initial MRCC Decision Period ; in such event, the MRCC Decision Period shall continue until the Renal Data is sufficient to so proceed, provided that in any event the MRCC Decision Period shall terminate up the earlier of ( i ) such time as there is no Collaboration Product for non - small cell lung or prostate tumors or melanomas in Phase I or later stage clinical development under the Development Program, or ( ii ) five ( 5 ) years after the Effective Date . J 6.6 [ Melanoma . ) CG agrees to promptly provide to JT after the Effective Date the of':M ~ el=-an - om - a Data . At any time prior to sixty ( 60 ) days after JT receives the 1Melanoma / Data ( the, e anoma Decision Period " ), JT shall have the right to retain either ( but not both ) non - small cell lung tumors ( or melanomij'Jin the Field by written notice to CG referencing this Section 6.6 and electing either or1"melanomas'j as the tumor type which JT desires to retain in the Field